Advances in personalized medicine of hematologic neoplasms and related pharmacogenetics / 白血病·淋巴瘤

ABSTRACT

The efficacy of hematological tumor drugs has shown inter-patient variability. Pharmacogenomics focuses on gene polymorphisms of drug metabolizing enzymes, drug transporters and therapeutic targets and its impact on pharmacokinetics (PK)/pharmacodynamics (PD). Initial dose and adverse reaction can be predicted based on inherited gene polymorphisms, and therapeutic drug monitoring (TDM) also helps to adjust drug dosage in the course of treatment. Thus can achieve rational drug use and personalized medicine, and improve the efficacy and reduce the incidence of adverse drug reactions. This article will introduce the relevant research progress in recent years, and the concept of personalized medication fingerprints is proposed.